In the crystal structure of a semi-synthetic opioid drug buprenorphine, C29H41NO4 {systematic name: (2S)-2-[(5R,6R,7R,14S)-9α-cyclo-propyl-methyl-3-hy-droxy-6-meth-oxy-4,5-ep-oxy-6,14-ethano-morphinan-7-yl]-3,3-di-methyl-butan-2-ol}, the cyclo-propyl-methyl group is disordered over two sites with an occupancy factor of 0.611 (3) for the major component. One of the hy-droxy groups is involved in intra-molecular O-H⋯O hydrogen bond. The other hy-droxy group acts as a proton donor in an inter-molecular O-H⋯O inter-action that connects mol-ecules into a zigzag chain along the b axis.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4051008 | PMC |
| http://dx.doi.org/10.1107/S1600536814009672 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Buprenorphine treatment and clinical outcomes under the opioid use disorder cascade of care.
Drug Alcohol Depend
October 2024
Department of Psychiatry, New York State Psychiatric Institute, Columbia University Medical Center, 1051 Riverside Dr., New York, NY 10032, United States; Research Foundation for Mental Hygiene, 1051 Riverside Dr, New York, NY 10032, United States.
Article Synopsis
- Most patients engaged in treatment for opioid use disorder (OUD) initially, but retention dropped significantly over time, with only 17.1% remaining in treatment after 24 months.
- Data showed that patients with opioid-positive tests at the start had a lower chance of achieving continuous abstinence, while those who tested opioid-negative had higher success rates.
- Early achievement of abstinence was crucial; patients who maintained sobriety for the first 6 months were much more likely to stay in treatment for the following year or two, highlighting the need for interventions aimed at supporting early stability in high-risk individuals.
Defining Discontinuation for Buprenorphine Treatment: Implications for Quality Measurement.
Am J Psychiatry
May 2024
Department of Psychiatry, New York State Psychiatric Institute, Columbia University Medical Center, New York (Williams, Olfson); Department of Biostatistics, Columbia University Mailman School of Public Health, New York (Mauro); Research Foundation for Mental Hygiene, New York (Huber); Addiction Research and Education Foundation, Florence, Mass. (Chiodo); North-Star Care, Inc., Gig Harbor, Wash. (Chiodo); University of Massachusetts Amherst, School of Nursing, Amherst, Mass. (Chiodo); Institute for Health, Health Care Policy, and Aging Research, Rutgers University, New Brunswick, N.J. (Crystal, Samples).
"I go out of my way to give them an extra smile now:" A study of pharmacists who participated in Respond to Prevent, a community pharmacy intervention to accelerate provision of harm reduction materials.
Res Social Adm Pharm
May 2024
Opioid Policy Research Collaborative, Heller School for Social Policy & Management at Brandeis University, Waltham, MA, USA; Departments of Emergency Medicine and Epidemiology, Brown Schools of Medicine and Public Health, Providence, RI, USA. Electronic address:
Background: Community pharmacies are well-positioned to improve the health of people with opioid use disorder and who use drugs by providing naloxone and other essential public health supplies. Respond to Prevent (R2P) is a clinical trial which sought to accelerate provision of harm reduction materials through a multicomponent intervention that included in-store materials, online training, and academic detailing.
Objectives: The objective of this study was to explore pharmacists' attitudes, knowledge, and experiences in providing naloxone, dispensing buprenorphine, and selling nonprescription syringes following participation in the R2P program.
A survey of barriers and facilitators to the adoption of buprenorphine prescribing after implementation of a New Jersey-wide incentivized DATA-2000 waiver training program.
BMC Health Serv Res
February 2024
Center for Health Services Research, Institute for Health, Health Care Policy and Aging Research, Rutgers, the State University of New Jersey, 112 Paterson St, 3rd Floor, New Brunswick, NJ, 08901, USA.
Background: Opioid-involved overdose deaths continue to rise in the US, despite availability of highly effective treatments for opioid use disorder (OUD), in part due to the insufficient number of treatment providers. Barriers include the need for providers to gain expertise and confidence in providing MOUD to their patients who need these treatments. To mitigate this barrier, New Jersey sponsored a buprenorphine training program with financial incentives for participation, which met the then existing requirement for the DATA-2000 waiver.
View Article and Find Full Text PDFUtilization and disparities in medication treatment for opioid use disorder among patients with comorbid opioid use disorder and chronic pain during the COVID-19 pandemic.
Drug Alcohol Depend
December 2023
Center for Opioid Epidemiology and Policy, Department of Population Health, NYU Grossman School of Medicine, New York, NY, United States.
Article Synopsis
- The COVID-19 pandemic did not significantly affect the overall utilization of medications for opioid use disorder (MOUD) among patients in New York State, but it did disrupt the initiation of treatment for those with chronic pain, particularly among racial/ethnic minority groups.
- Among 20,785 patients, those with chronic pain showed lower utilization rates of MOUD (49.3%) compared to those without (60.3%).
- The findings highlight ongoing disparities in access to care and treatment initiation for minorities, suggesting a need for targeted policy measures to address these inequities.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!